We studied the emergence of drug-resistant human immunodeficiency virus type 1 (HIV-1) with major amino acid mutations in 402 therapy-naive patients at Nagoya Medical Center, Japan, between 1999 and 2006. The mean prevalence of drug-resistant HIV-1 was 6.7% (range, 2.3-10.0%; n ‫؍‬ 27). HIV-1 variants with protease inhibitor (PI)-resistant mutations alone were most frequently found (3.5%, n ‫؍‬ 
INTRODUCTION C
OMBINATION THERAPY with three or more antiretroviral drugs (highly active antiretroviral therapy, HAART) can strongly suppress the replication of human immunodeficiency virus type 1 (HIV-1) and maintain the amount of HIV-1 RNA in plasma (viral load) under detectable levels in many cases. [1] [2] [3] [4] [5] However, HIV-1 variants with decreased susceptibility to antiretroviral drugs are sometimes found under conditions in which the drug concentration is insufficient to suppress viral replication following poor adherence to treatment regimens. [4] [5] [6] [7] [8] [9] Such variants might become an origin for HIV-1 transmission, resulting in the finding of drug-resistant HIV-1 in therapy-naive individuals.
This represents a serious problem in therapy, as such variants hinder antiretroviral therapy from the first trial. [10] [11] [12] [13] [14] [15] [16] Determining whether therapy-naive patients are infected by drug-resistant HIV-1 before starting HAART is thus important. The present study studied emergence trends for drug-resistant HIV-1 with major mutations among therapy-naive patients in the Nagoya Medical Center, Japan, between 1999 and 2006. We also studied the emergence of HIV-1 with 215-revertant amino acid mutations in the reverse transcriptase (RT), as 215-revertant variants can easily change to nucleoside RT inhibitor (NRTI)-resistant variants. [17] [18] [19] [20] The final aim of the study was to understand the epidemiological nature of drug-resistant variants and obtain information to successfully block their spread.
MATERIALS AND METHODS

Patients
A total of 441 therapy-naive HIV-1-infected patients underwent their initial consultation at Nagoya Medical Center in Nagoya, Japan, between January 1999 and December 2006. Genotypic drug-resistance testing for HIV-1 was performed on 402 of the 441 patients (91%) after obtaining patient consent. The characteristics of the 402 patients are shown in Table 1 .
Genotypic drug-resistance testing for HIV-1
Genotypic drug-resistance testing for HIV-1 was performed as previously reported. 21, 22 HIV-1 RNA was purified from a plasma sample using a QIAamp viral RNA mini kit (QIAGEN, Tokyo, Japan). A single DNA fragment containing both protease (PR) and reverse transcriptase (RT) genes was amplified by reverse transcription-nested polymerase chain reaction (RTnested PCR) using the Superscript one-step RT-PCR for long templates kit (Invitrogen, Tokyo, Japan) and LA Taq polymerase (Takara, Shiga, Japan). A labeling reaction for DNA sequencing was performed using the BigDye terminator cycle sequencing kit (Applied Biosystems, Tokyo, Japan), and DNA sequences were determined by the direct sequencing method using an ABI PRISM 310 Genetic Analyzer (Applied Biosystems). DNA sequences were converted to amino acid sequences, and then amino acid mutations were extracted through comparison with amino acid sequences of the HIV-1 HXB2 strain. Judgment of drug-resistant amino acid mutations was performed according to the latest version of the International AIDS Society USA panel, Fall 2006. 23 
Phylogenetic analysis
Phylogenetic analysis was performed using the nucleotide sequences of HIV-1 obtained from all 402 therapy-naive patients. Nucleotide sequences (1005 bases) containing both PR (codons 1-99) and RT (codons 1-236) genes were used. Multiple sequence alignment was performed using CLUSTAL W, and evolutionary distances were calculated using the Kimura two-parameter model. A phylogenetic tree was constructed by the neighbor-joining method with 1000 bootstrap replicates. These analyses were performed using MEGA software version 3.1. 24 Nucleotide sequences of 32 reference HIV-1 strains were obtained from the HIV sequence database in the Los Alamos National Laboratory. Subtyping of HIV-1 was also performed using the phylogenetic tree.
Measurement of viral load and CD4 cell count
Viral load was measured using an Amplicor HIV-1 monitor v1.5 system (Roche Diagnostics, Tokyo, Japan). CD4 cell counts were measured using a FACSCalibur flow cytometry system (Becton Dickinson, Tokyo, Japan).
Statistics
Multiple logistic regression analysis was performed to assess associations between patient characteristics and infection with drug-resistant or 215-revertant HIV-1 variants. Values of p Ͻ 0.05 were considered statistically significant. Analyses were performed using SYSTAT version 10.2 software (SYSTAT Software, California, USA).
RESULTS
Emergence trend of drug-resistant HIV-1 in therapy-naive patients
The prevalence of drug-resistant HIV-1 fluctuated between 2.3% and 10.0% through the period from 1999 to 2006 ( 
Characteristics of drug-resistant HIV-1
Characteristics of drug-resistant HIV-1 found in our surveillance are shown in Table 2 . The most frequently found variant was a PI-resistant virus with the M46I mutation alone (n ϭ 12), followed by an NNRTI-resistant virus with the K103N mutation alone (n ϭ 4). Variants with two-class resistance were found in two cases, one possessing both PR-and NNRTI-resistant mutations, and the other with both PI-and NRTI-resistant mutations. Of note is the fact that no virus with resistance against all three classes was found in our surveillance.
Emergence trends for HIV-1 variants possessing the 215-revertant amino acid mutation in the reverse transcriptase
T215A/C/D/E/G/H/I/L/N/S/V amino acid substitutions in the RT represent revertant mutations of the T215Y/F NRTI-resistant mutation. 23 The 215-revertant mutations do not exhibit NRTI resistance by themselves, but most can reconvert to the T215Y/F NRTI-resistant mutation by acquiring a single nucleotide mutation. In other word, most 215-revertant variants can much more easily change to NRTI-resistant variants under the pressure of NRTIs than wild-type HIV-1. [17] [18] [19] [20] We feel drug-resistant variants with the T215Y/F mutation are difficult to survive in the drug-free condition, as only one variant with the T215Y mutation has been found during an 8-year surveillance. The results of other researchers support our feelings. 17, 18 Examination of the emergence of the 215-revertant variant in addition to the T215Y/F-possessing resistant variant is thus important. In our surveillance, variants possessing the T215A/ C/D/E/G/L/S mutation were found in 21 cases; since T215G/D was found in 2000, such variants have been increasing (Fig.  2D ). Among these, 17 cases (81%) can reconvert to the T215Y/F NRTI-resistant mutation by acquiring a single nucleotide mutation.
Phylogenetic analysis
This study identified 27 drug-resistant variants from 402 therapy-naive patients. We next performed phylogenetic analysis to clarify whether specific drug-resistant strains were spreading. Three different clusters were identified from 20 of 27 drug-resistant variants (#1-13, #14-18, and #19-20) on a phylogenetic tree (Fig. 3A) . All the clusters were consisted of subtype B viruses. The remaining seven variants were dispersed over the tree (Fig. 3A, #21-27 ). Two out of the seven were non-B viruses, subtype D and CRF01_AE. Detailed divergence of 
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the 13 PI-resistant variants (#1-13) with the M46I or L90M mutation is shown in Fig. 3B , indicating derivatives from a common ancestral strain. Four NNRTI-resistant variants and a two class-resistant variant possessing the K103N mutation formed another cluster (Fig. 3C, #14-18 ). Concerning the 215-revertant variants, 19 of 21 variants formed an independent cluster (Fig. 3A, #28-46; Fig. 3D (Fig. 3) .
Statistical analysis
No significant differences in age, sex, nationality, risk factors for infection, CD4 cell count, viral load, or HIV-1 subtype were seen between patients with drug-resistant or 215-revertant variants and patients with wild-type viruses (data not shown).
DISCUSSION
The prevalence of drug-resistant HIV-1 among therapynaive patients in Nagoya, Japan, was studied from 1999 to 2006. The mean prevalence was 6.7% (27/402), which is lower than that reported recently from European and North American countries (8.1-25.2%), [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] but a tendency has recently been seen for increasing prevalence. Actually, prevalence has already exceeded the level at which the implementation of drug-resistance testing on therapy-naive patients is cost effective. 38, 39 Over the past 8 years, the most abundant drug-resistant HIV-1 strains have been PI-resistant variants (3.5%, n ϭ 14), and most have possessed the M46I mutation alone. The second most abundant variants were NNRTI-resistant HIV-1 (1.7%, n ϭ 7), most of which possessed the K103N mutation. This type of variant with K103N was first found in therapy-naive patients in 2003. As the corresponding NNRTIs of nevirapine, efavirenz, and delavirdine were approved in Japan from 1998 to 2000, 3-5 years will be needed for the appearance of drug-resistant amino acid mutations in therapy-naive individuals after the start of drug usage. The sporadic finding of NRTI-resistant variants (1.0%, n ϭ 4) in our surveillance seems curious, as NRTIs have been in use since 1987 in Japan. However, this may be explained by the finding that many HIV-1 variants with revertant mutations of the T215Y/F NRTI-resistant mutation have frequently been identified since 2000. Moreover, most (81%, 17/21) possessed 215-reveratant mutations that could reconvert to the T215Y/F NRTI-resistant mutation through a single nucleotide change. Such highly resistant variants as three classresistant variants have not yet been found, but two class-resistant variants were first identified in 2006.
Phylogenetic analysis yielded very important information, indicating that two independent major drug-resistant strains have been spreading in the Nagoya area, one possessing the M46I or L90M mutation and another possessing the K103N mutation. Furthermore, for 215-revertant variants, 19 of 21 variants were derivatives from the same strain, and have been independently spreading from 2000.
The present study succeeded in clarifying the epidemiological nature of drug-resistant variants and 215-reveratant variants in Nagoya, Japan. Our data will provide information valuable for attempts to block the spread of these variants.
SEQUENCE DATA
The base sequences of drug-resistant HIV-1, 215-revertant HIV-1, and wild-type HIV-1 have been registered in the DNA databank of Japan (DDBJ) as #AB356098-AB356124, #AB356125-AB356145, and #AB356146-AB356499, respectively. 
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